news
Dementia Patients Over-Sedated in Long-Term Care, Feds Say
Federal efforts to curb the use of potent sedating drugs for agitated dementia patients in long-term care are failing. A KFF Health News report details families struggling to keep loved ones off these medications, highlighting the pervasive practice despite medical guidelines.
Federal efforts to curb the use of potent sedating drugs for agitated dementia patients in long-term care are failing. A KFF Health News report details families struggling to keep loved ones off these medications, highlighting the pervasive practice despite medical guidelines.
The architecture take
This isn't a new story, but it's one we keep needing to hear: the systemic over-sedation of vulnerable populations. When someone's prefrontal cortex is already struggling, adding potent anticholinergic or antipsychotic meds just crushes any remaining cognitive function and often worsens agitation long-term, not improves it. The body knows. For decades, the FDA and other regulators have flagged the risks, including increased mortality for older adults on antipsychotics, but the path of least resistance for understaffed facilities too often remains pharmacological restraint. This piece is a sharp reminder that a calm nervous system isn't always the goal, sometimes it's just a convenient side effect of compliance. Families end up fighting for basic dignity, trying to restore any scrap of their loved one's baseline state. Pay attention to what's happening to the most vulnerable; it's a canary in the coal mine for how we treat everyone.